301015 Qingdao Baheal Medical INC.
- 28.77
- -0.52-1.78%
Qingdao Baheal Medical INC. News
Baiyang Pharmaceutical: Prompt Notice on Responses to Audit Inquiries on Applications for Issuance of Convertible Corporate Bonds to Unspecified Targets and Application Documents such as Prospectus to update financial data
Baiyang Pharmaceutical: Lixin Certified Public Accountants (Special General Partnership) Response Report to the “Second Audit Inquiry Letter on Qingdao Baiyang Pharmaceutical Co., Ltd.'s Application to Issue Convertible Corporate Bonds to Unspecified Targe
Baiyang Pharmaceutical: Responses from Qingdao Baiyang Pharmaceutical Co., Ltd. and Dongxing Securities Co., Ltd. to the “Second Audit Inquiry Letter on Qingdao Baiyang Pharmaceutical Co., Ltd.'s Application for Issuance of Convertible Corporate Bonds to U
Baiyang Pharmaceutical: Response of Qingdao Baiyang Pharmaceutical Co., Ltd. and Dongxing Securities Co., Ltd. to the “Audit Inquiry Letter on Qingdao Baiyang Pharmaceutical Co., Ltd.'s Application for Issuance of Convertible Corporate Bonds to Unspecified
Baiyang Pharmaceutical: Lixin Certified Public Accountants (Special General Partnership) Response Report to the “Audit Inquiry Letter Concerning Qingdao Baiyang Pharmaceutical Co., Ltd.'s Application for Issuance of Convertible Corporate Bonds to Unspecifi
Baiyang Pharmaceutical: Announcement on the Passively Formation of Financial Assistance by Related Claims After Selling Shares in Holding Subsidiaries
Baiyang Pharmaceutical: 3 Supplemental Legal Opinions (1) (Revised Draft)
Baiyang Pharmaceutical: 2 Accountant's Response to the Audit Enquiry Letter (Revised Draft)
Baiyang Pharmaceuticals: 1 Responses from issuers and sponsors to the review inquiry letter (revised draft)
Baiyang Pharmaceutical: 6-1 The issuer's financial report for the last three years and its audit report and the most recent financial report (for the most recent financial report, please submit the recently announced financial report) (Report)
Baiyang Pharmaceutical: 4-1 Legal Opinion (Report Draft)
Baiyang Pharmaceutical: 3-3 Listing Sponsorship Letter (Application Draft)
Baiyang Pharmaceutical: 3-1 Securities Issuance Sponsorship Letter (Report Draft)
Baiyang Pharmaceutical: 1-1 Application Instructions (Application Draft)
Baiyang Pharmaceutical: Beijing Tianyuan Law Firm's Supplementary Legal Opinion on the Issuance of Convertible Corporate Bonds by Qingdao Baiyang Pharmaceutical Co., Ltd. to Unspecified Targets (1) (Revised Draft)
Baiyang Pharmaceutical: Prompt Notice on Responses to Audit Inquiries on Applications for Issuance of Convertible Corporate Bonds to Unspecified Targets and Application Documents such as Prospectus to update financial data
Baiyang Pharmaceutical: Response to the audit inquiry letter from Qingdao Baiyang Pharmaceutical Co., Ltd. and Dongxing Securities Co., Ltd. regarding the issuance of convertible corporate bonds to unspecified targets (revised draft)
Baiyang Pharmaceutical: Dongxing Securities Co., Ltd.'s listing sponsor for the issuance of convertible corporate bonds to unspecified targets on the GEM of Qingdao Baiyang Pharmaceutical Co., Ltd.
Baiyang Pharmaceutical: 2021 Equity Distribution Implementation Notice
Baiyang Pharmaceutical: Feasibility Analysis Report on the Use of Funds Raised by Issuing Convertible Corporate Bonds to Unspecified Targets (Revised Draft)
Analysis
Price Target
No Data
